PH12015502075B1 - Treatment of cataplexy - Google Patents

Treatment of cataplexy

Info

Publication number: PH12015502075B1
Authority: PH; Philippines
Prior art keywords: cataplexy; treatment; subject; administering; need
Prior art date: 2013-03-13

Application number

PH12015502075A

Other languages

English (en)

Other versions

PH12015502075A1 (en

Inventor

Moise A Khayrallah

Gary Bream

Stephen E Butts

Original Assignee

Aerial Biopharma Llc

Sk Biopharmaceuticals Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2015-09-11

Publication date

2016-01-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015502075(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-09-11 Application filed by Aerial Biopharma Llc, Sk Biopharmaceuticals Co Ltd filed Critical Aerial Biopharma Llc

2016-01-18 Publication of PH12015502075B1 publication Critical patent/PH12015502075B1/en

2016-01-18 Publication of PH12015502075A1 publication Critical patent/PH12015502075A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PH12015502075A 2013-03-13 2015-09-11 Treatment of cataplexy PH12015502075A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361778998P	2013-03-13	2013-03-13
PCT/US2014/023969 WO2014164969A1 (en)	2013-03-13	2014-03-12	Treatment of cataplexy

Publications (2)

Publication Number	Publication Date
PH12015502075B1 true PH12015502075B1 (en)	2016-01-18
PH12015502075A1 PH12015502075A1 (en)	2016-01-18

Family

ID=51530017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH12015502075A PH12015502075A1 (en)	2013-03-13	2015-09-11	Treatment of cataplexy

Country Status (21)

Country	Link
US (7)	US9359290B2 (zh)
EP (1)	EP2968208B1 (zh)
JP (2)	JP6530741B2 (zh)
KR (1)	KR102192554B1 (zh)
CN (1)	CN105431142B (zh)
AU (1)	AU2014248849B2 (zh)
BR (1)	BR112015022197B1 (zh)
CA (1)	CA2905457A1 (zh)
DK (1)	DK2968208T3 (zh)
ES (1)	ES2927675T3 (zh)
HR (1)	HRP20221018T1 (zh)
HU (1)	HUE060060T2 (zh)
MX (1)	MX381381B (zh)
MY (1)	MY177740A (zh)
PH (1)	PH12015502075A1 (zh)
PT (1)	PT2968208T (zh)
RU (2)	RU2689984C2 (zh)
SG (1)	SG11201507121RA (zh)
SI (1)	SI2968208T1 (zh)
TW (2)	TWI684450B (zh)
WO (1)	WO2014164969A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI419681B (zh) *	2005-06-08	2013-12-21	Ｓｋ生物製藥股份有限公司	胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
JP6095366B2 (ja) *	2009-06-22	2017-03-15	エスケーバイオファーマシューティカルズカンパニーリミテッド	疲労を治療又は予防するための方法
PT2968208T (pt) *	2013-03-13	2022-10-28	Aerial Biopharma Llc	Tratamento da cataplexia
EP3021838B1 (en)	2013-07-18	2020-05-27	Jazz Pharmaceuticals Ireland Limited	Treatment for obesity
US12478604B1 (en)	2016-07-22	2025-11-25	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en)	2016-07-22	2025-01-07	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en)	2016-07-22	2022-11-22	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es)	2016-07-22	2017-11-30	Flamel Ireland Ltd	Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en)	2016-07-22	2024-05-21	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
ES2970887T3 (es)	2016-09-06	2024-05-31	Axsome Malta Ltd	Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) *	2016-09-06	2019-02-05	Jazz Pharmaceuticals International Iii Limited	Formulations of (R)-2-amino-3-phenylpropyl carbamate
WO2018067971A1 (en)	2016-10-06	2018-04-12	Jazz Pharmaceuticals International Iii Limited	Carbamoyl phenylalaninol compounds and uses therof
EP3630072A4 (en) *	2017-06-02	2021-03-10	Jazz Pharmaceuticals Ireland Limited	METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
RU2020108634A (ru)	2017-07-31	2021-09-02	Джаз Фармасьютикалз Айрлэнд Лимитед	Аналоги карбамоилфенилаланинола и способы их применения
AU2018331326A1 (en) *	2017-09-12	2020-03-19	Ovid Therapeutics Inc.	Use of gaboxadol in the treatment of narcolepsy
CN111867573A (zh)	2018-01-29	2020-10-30	科诺斯治疗学公司	硼替佐米的瘤内递送
US20190381056A1 (en)	2018-06-17	2019-12-19	Axsome Therapeutics, Inc.	Compositions for delivery of reboxetine
WO2021113163A1 (en) *	2019-12-03	2021-06-10	Axsome Therapeutics, Inc.	Use of reboxetine to treat nervous system disorders
BR112021007019A2 (pt) *	2018-10-15	2021-07-13	Axsome Therapeutics, Inc.	uso de reboxetina para tratar narcolepsia
US20200147093A1 (en) *	2018-10-15	2020-05-14	Axsome Therapeutics, Inc.	Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en)	2018-10-15	2021-06-01	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
US11400065B2 (en)	2019-03-01	2022-08-02	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
EP4069244A4 (en) *	2019-12-03	2023-12-20	Axsome Therapeutics, Inc.	USING REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
TW202139986A (zh)	2020-02-21	2021-11-01	愛爾蘭商爵士製藥愛爾蘭有限責任公司	治療原發性嗜睡症之方法
US10940133B1 (en)	2020-03-19	2021-03-09	Jazz Pharmaceuticals Ireland Limited	Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) *	2020-08-03	2022-04-25	셀라이온바이오메드 주식회사	페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11779557B1 (en)	2022-02-07	2023-10-10	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en)	2022-02-07	2023-02-21	Flamel Ireland Limited	Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
AU2024308064A1 (en)	2023-06-29	2026-01-22	Axsome Therapeutics, Inc.	Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) *	2023-08-21	2025-02-27	Axsome Therapeutics, Inc.	Use of solriamfetol for the treatment of orphan diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US178429A (en) *		1876-06-06		Improvement in hulling-machines
NZ314570A (en)	1993-06-10	2000-11-24	Lilly Co Eli	Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko)	1994-09-09	1999-06-15	남창우	신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko)	1995-02-11	1999-04-01	조규향	O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en)	1995-02-11	2001-04-17	Sk Corp	O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko)	1995-04-10	1999-04-01	조규향	페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en)	1996-10-10	2002-01-02	SK Corporation	O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
AU4674797A (en)	1996-10-22	1998-05-15	Ortho Pharmaceutical Corporation	Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) *	1999-09-17	2001-03-20	The Regents Of The University Of California	Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) *	2001-04-11	2001-05-30	Pfizer Ltd	Novel compounds
US20030207857A1 (en)	2001-04-11	2003-11-06	Adam Mavis D.	Phenyl heterocyclyl ethers
US20050080268A1 (en)	2003-10-08	2005-04-14	Yong-Moon Choi	Process of preparing O-carbamoyl compounds in the presence of active amine group
ATE490959T1 (de) *	2004-03-31	2010-12-15	Janssen Pharmaceutica Nv	Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
JP2008512386A (ja) *	2004-09-07	2008-04-24	オーファンメディカル，インコーポレイティド	改良型ｇｈｂ組成物
CA2587481A1 (en)	2004-10-28	2006-05-11	Sk Corporation	Phenylalkylamino carbamates adjunctive therapy for depression
TWI419681B (zh) *	2005-06-08	2013-12-21	Ｓｋ生物製藥股份有限公司	胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
ES2344469T3 (es)	2005-06-22	2010-08-27	Sk Holdings Co., Ltd.	Tratamiento de disfuncion sexual.
KR101199499B1 (ko)	2005-07-26	2012-11-09	얀센 파마슈티카 엔.브이.	물질 관련 장애를 치료하는 방법
FR2903904A1 (fr) *	2006-07-21	2008-01-25	Bioprojet Soc Civ Ile	Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
US20080090902A1 (en)	2006-10-13	2008-04-17	Pandey Ramendra N	Phenylalkylamino carbamate compositions
EP2605015A1 (en) *	2006-11-10	2013-06-19	Dimerix Bioscience Pty.Ltd.	Kits for determining the interaction of a test compound with two associated receptors
JP6095366B2 (ja)	2009-06-22	2017-03-15	エスケーバイオファーマシューティカルズカンパニーリミテッド	疲労を治療又は予防するための方法
US8232315B2 (en)	2009-06-26	2012-07-31	Sk Biopharmaceuticals Co., Ltd.	Methods for treating drug addiction and improving addiction-related behavior
CN102762201B (zh)	2009-11-06	2013-12-18	爱思开生物制药株式会社	注意力缺陷/多动症的治疗方法
EP2496227B1 (en)	2009-11-06	2019-05-22	SK Biopharmaceuticals Co., Ltd.	Methods for treating fibromyalgia syndrome
US9610274B2 (en)	2010-06-30	2017-04-04	Sk Biopharmaceuticals Co., Ltd.	Methods for treating bipolar disorder
US8623913B2 (en)	2010-06-30	2014-01-07	Sk Biopharmaceuticals Co., Ltd.	Methods for treating restless legs syndrome
PT2968208T (pt) *	2013-03-13	2022-10-28	Aerial Biopharma Llc	Tratamento da cataplexia

2014
- 2014-03-12 PT PT147780886T patent/PT2968208T/pt unknown
- 2014-03-12 HR HRP20221018TT patent/HRP20221018T1/hr unknown
- 2014-03-12 MX MX2015012644A patent/MX381381B/es unknown
- 2014-03-12 DK DK14778088.6T patent/DK2968208T3/da active
- 2014-03-12 US US14/205,423 patent/US9359290B2/en active Active
- 2014-03-12 ES ES14778088T patent/ES2927675T3/es active Active
- 2014-03-12 TW TW108107074A patent/TWI684450B/zh active
- 2014-03-12 BR BR112015022197-1A patent/BR112015022197B1/pt active IP Right Grant
- 2014-03-12 AU AU2014248849A patent/AU2014248849B2/en active Active
- 2014-03-12 HU HUE14778088A patent/HUE060060T2/hu unknown
- 2014-03-12 EP EP14778088.6A patent/EP2968208B1/en active Active
- 2014-03-12 SG SG11201507121RA patent/SG11201507121RA/en unknown
- 2014-03-12 RU RU2015143610A patent/RU2689984C2/ru active
- 2014-03-12 CA CA2905457A patent/CA2905457A1/en not_active Abandoned
- 2014-03-12 JP JP2016501395A patent/JP6530741B2/ja active Active
- 2014-03-12 KR KR1020157027978A patent/KR102192554B1/ko active Active
- 2014-03-12 CN CN201480027152.9A patent/CN105431142B/zh active Active
- 2014-03-12 WO PCT/US2014/023969 patent/WO2014164969A1/en not_active Ceased
- 2014-03-12 RU RU2019114940A patent/RU2019114940A/ru not_active Application Discontinuation
- 2014-03-12 SI SI201431991T patent/SI2968208T1/sl unknown
- 2014-03-12 TW TW103108612A patent/TWI663971B/zh active
- 2014-03-12 MY MYPI2015703166A patent/MY177740A/en unknown
2015
- 2015-09-11 PH PH12015502075A patent/PH12015502075A1/en unknown
2016
- 2016-05-09 US US15/149,478 patent/US9585863B2/en active Active
2017
- 2017-01-30 US US15/419,133 patent/US10259780B2/en active Active
2019
- 2019-03-20 US US16/359,446 patent/US11072579B2/en active Active
- 2019-05-17 JP JP2019093823A patent/JP2019147830A/ja active Pending
2021
- 2021-07-23 US US17/383,707 patent/US11713292B2/en active Active
2023
- 2023-06-19 US US18/337,299 patent/US12162821B2/en active Active
2024
- 2024-11-04 US US18/935,803 patent/US20250059135A1/en active Pending

Also Published As

Publication number	Publication date
JP6530741B2 (ja)	2019-06-12
HRP20221018T1 (hr)	2023-01-06
AU2014248849A1 (en)	2015-10-08
DK2968208T3 (da)	2022-08-22
US10259780B2 (en)	2019-04-16
BR112015022197A2 (pt)	2017-07-18
WO2014164969A1 (en)	2014-10-09
US11072579B2 (en)	2021-07-27
EP2968208B1 (en)	2022-07-20
US20170137375A1 (en)	2017-05-18
JP2016512531A (ja)	2016-04-28
RU2019114940A (ru)	2019-06-28
US20190218174A1 (en)	2019-07-18
ES2927675T3 (es)	2022-11-10
US9585863B2 (en)	2017-03-07
HUE060060T2 (hu)	2023-01-28
JP2019147830A (ja)	2019-09-05
MX381381B (es)	2025-03-12
US20160250176A1 (en)	2016-09-01
US12162821B2 (en)	2024-12-10
SG11201507121RA (en)	2015-10-29
EP2968208A4 (en)	2016-10-12
BR112015022197A8 (pt)	2019-11-26
US20250059135A1 (en)	2025-02-20
RU2015143610A3 (zh)	2018-03-21
TWI663971B (zh)	2019-07-01
TWI684450B (zh)	2020-02-11
SI2968208T1 (sl)	2023-02-28
KR102192554B1 (ko)	2020-12-18
US20230416195A1 (en)	2023-12-28
US20140275244A1 (en)	2014-09-18
HK1219236A1 (zh)	2017-03-31
KR20150139522A (ko)	2015-12-11
PT2968208T (pt)	2022-10-28
US9359290B2 (en)	2016-06-07
MY177740A (en)	2020-09-23
CN105431142B (zh)	2019-04-26
TW201513856A (zh)	2015-04-16
BR112015022197B1 (pt)	2022-06-07
CA2905457A1 (en)	2014-10-09
EP2968208A1 (en)	2016-01-20
RU2019114940A3 (zh)	2019-12-25
TW201919606A (zh)	2019-06-01
RU2689984C2 (ru)	2019-05-30
US11713292B2 (en)	2023-08-01
RU2015143610A (ru)	2017-04-20
CN105431142A (zh)	2016-03-23
PH12015502075A1 (en)	2016-01-18
MX2015012644A (es)	2016-06-21
AU2014248849B2 (en)	2018-08-30
US20220017457A1 (en)	2022-01-20

Publication	Publication Date	Title
PH12015502075B1 (en)	2016-01-18	Treatment of cataplexy
ZA201708692B (en)	2024-07-31	Antibacterial compounds
EA201690206A1 (ru)	2016-05-31	Терапевтически активные соединения и способы их применения
PH12016500164B1 (en)	2023-11-08	Therapeutically active compounds and their methods of use
BR112018003526A2 (pt)	2018-09-25	métodos de tratamento de doenças inflamatórias
MY194341A (en)	2022-11-29	Method of treating a brain tumor
HK1256042A1 (zh)	2019-09-13	用於治疗糖尿病周围神经病变的hdac抑制剂
EA201690039A1 (ru)	2016-08-31	Ингибиторы rorc2 и способы их применения
PH12015500169A1 (en)	2015-03-16	Prediction of treatment response to jak/stat inhibitor
EA201591507A1 (ru)	2015-12-30	Лечение рассеянного склероза лахинимодом
NZ722600A (en)	2023-06-30	Methods of treating mild brain injury
PH12016500903A1 (en)	2016-06-20	Novel methods for treating neurodegenerative diseases
PH12014502065A1 (en)	2014-12-10	Vesicular formulations
MX382608B (es)	2025-03-13	Tratamiento del prurito urémico.
EA201690446A1 (ru)	2016-06-30	Лечение множественной миеломы
EA201690445A1 (ru)	2016-06-30	Лечение рака
MX2017007245A (es)	2018-02-16	Metodos de tratamiento de la fibrosis.
MX374354B (es)	2025-03-06	Método de curación de heridas.
EA201691036A1 (ru)	2016-12-30	Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru)	2016-09-30	Новое соединение для лечения тяжелой гипогликемии
NZ724799A (en)	2023-07-28	Compositions and methods for the treatment or prevention of neurodegenerative disorders
UA114811C2 (uk)	2017-08-10	Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
NZ750581A (en)	2020-08-28	Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12014000104A1 (en)	2015-09-28	Therapeutic methods and compositions for treating diabetes